USPSTF on PSA screening … a current update …

The U.S. Preventive Services Task Force (USPSTF) has just issued its “Guide to Clinical Preventive Services” for 2014. The publication (which is available on line) includes summary information about screening for prostate cancer. … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

“A plea for individualized prostate cancer screening”

For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …

Shared and emotion-free decision-making with respect to PSA-based screening

The following is (slightly edited) report by Jeffrey J. Tomaszewski, MD, on behalf of UroToday.com, of a state-of-the-art lecture by David Penson, MD, presented at the annual meeting of the American Urological Association (AUA) in Orlando. We hope that UroToday will forgive us for this direct “theft”, but the topic is one of enormous relevance to the patient community. … READ MORE …

Liu and Zoey “are Ferraris” who massively outperform PSA testing

A report on the Medscape Oncology site on Tuesday discussed prostate cancer detection data presented at the annual meeting of the American Urological Association (AUA) by a group of Italian researchers — with the help of two highly trained German Shepherds. … READ MORE …

A 13-year update from the ERSPC screening trial

So one of the presentations given at the recent EAU meeting in Stockholm was an update, by Dr. Jonas Hugosson, at a median 13 years of follow-up, from the European Randomized Study of Screening for Prostate Cancer (ERSPC)  — and there is some good news, but maybe not enough to get carried away by … yet. READ MORE …

“Five golden rules” for prostate cancer screening and treatment today

In a very simple and straightforward article in European Urology, Vickers et al. have clearly laid out a series of five “golden rules” that, in their opinion, all physicians should be following today when they are testing men for risk of prostate cancer through the use of the PSA test. … READ MORE …

More data that will cause controversy in the screening debate

Data from a very large, 25-year-long, randomized, controlled trial of screening for cancer has cast further doubt on the value of mass, annual, population-based screening as a way to reduce cancer deaths. … READ MORE …

UroToday interviews with D’Amico, Klotz, Mulhall

Many readers of this blog may be interested in listening to one or more of a series of recent, relatively short audio-interviews with respected opinion-leaders in the prostate cancer diagnosis and management community, conducted by the medical director of UroToday. … READ MORE …

EAU updates guidelines on screening, diagnosis, and management of localized prostate cancer

The European Association of Urology (EAU) has just updated its guideline document “EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent”. … READ MORE …

Did unequal use of ADT in treatment affect mortality rates in the ERSPC and Göteborg trials?

A new article by Australian researchers in the Journal of the National Cancer Institute has suggested that the more widespread use of androgen deprivation therapy (ADT) among unscreened patients (controls) in the ERSPC and the Göteborg studies may have substantially affected patient mortality data in these trials. … READ MORE …

Poor guidance from the AAFP, badly interpreted by the media

According to a recent recommendation from the American Academy of Family Physicians in association with the Choosing Wisely campaign. primary care physicians are being advised as follows: … READ MORE …

Screening and its consequences: an interview with Laura Esserman

Yesterday, Medscape Oncology published a brief interview with Dr. Laura Esserman (under the title “Cancer screening: when less is more“) that will be of interest to a number of our regular readers. … READ MORE …

The PSA screening controversy: two new pro/con presentations

The “New” Prostate Cancer InfoLink finds it fascinating how, while sticking to their guns about the value of “screening” healthy men for risk of prostate cancer, the two differing groups of advocates (those “for/pro” screening and those “against/con” its) are still failing to appropriately emphasize that they are using the word “screening” with differing intent. … READ MORE …

Urologists’ and radiation oncologists’ opinions on use of PSA test to screen for prostate cancer

A new study has provided data on the opinions of a random sample of 1,366 radiation oncologists and urologists with regard to the appropriate role of the PSA test in screening for prostate cancer (since the recommendation of a D grade for this test as a screening mechanism by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers